

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

2315 Selected Articles from This Issue

## MCT FIRST DISCLOSURES

2317 **Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity**

Dirk Brehmer, Lijs Beke, Tongfei Wu, Hillary J. Millar, Christopher Moy, Weimei Sun, Geert Mannens, Vineet Pande, An Boeckx, Erika van Heerde, Thomas Nys, Emmanuel M. Gustin, Bie Verbist, Longen Zhou, Yue Fan, Vipul Bhargava, Pegah Safabakhsh, Petra Vinken, Tinne Verhulst, Angelique Gilbert, Sumit Rai, Timothy A. Graubert, Friederike Pastore, Danilo Fiore, Junchen Gu, Amy Johnson, Ulrike Philippa, Barbara Morschhäuser, David Walker, Desiree De Lange, Vikki Keersmaekers, Marcel Viellevoye, Gaston Diels, Wim Schepens, Jan Willem Thuring, Lieven Meerpoel, Kathryn Packman, Matthew V. Lorenzi, and Sylvie Laquerre

2329 **Datopotamab Deruxtecán, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells**

Daisuke Okajima, Satoru Yasuda, Takanori Maejima, Tsuyoshi Karibe, Ken Sakurai, Tetsuo Aida, Tadashi Toki, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, Tomoyo Honda, Tomoko Shibutani, Sumie Muramatsu, Takashi Nakada, Riki Goto, Shu Takahashi, Miki Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Masato Murakami, Yuki Abe, and Toshinori Agatsuma

## REVIEW

2341 **SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy**

Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, Shumei Kato, and Razelle Kurzrock

## SMALL MOLECULE THERAPEUTICS

2352 **Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models**

Katelyn F. Handley, Cristian Rodriguez-Aguayo, Shaolin Ma, Elaine Stur, Robiya Joseph, Emine Bayraktar, Santosh K. Dasari, Nghi Nguyen, Reid T. Powell, Mary Sobieski, Cristina Ivan, Mark Kim, Sujanitha Umamaheswaran, Deanna Glassman, Yunfei Wen, Paola Amero, Clifford Stephan, Robert L. Coleman, Yosef Landesman, Shannon N. Westin, Prahlad T. Ram, and Anil K. Sood

2362 **Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors**

Tahir N. Sheikh, Xiao Chen, Xinjing Xu, John T. McGuire, Matthew Ingham, Chao Lu, and Gary K. Schwartz

2372 **Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506**

Alexander M.A. van der Wiel, Victoria Jackson-Patel, Raymon Niemans, Ala Yaromina, Emily Liu, Damiëne Marcus, Alexandra M. Mowday, Natasja G. Liewes, Rianne Biemans, Xiaojing Lin, Zhe Fu, Sisira Kumara, Arthur Jochems, Amir Ashoorzadeh, Robert F. Anderson, Kevin O. Hicks, Matthew R. Bull, Maria R. Abbattista, Christopher P. Guise, Sofie Deschoemaeker, Sophie Thiolloy, Arne Heyerick, Morwena J. Solivio, Silvia Balbo, Jeff B. Smail, Jan Theys, Ludwig J. Dubois, Adam V. Patterson, and Philippe Lambin

2384 **NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment**

Tiange Dong, Priyal Dave, EunJeong Yoo, Brandon Ebright, Kabir Ahluwalia, Eugene Zhou, Isaac Asante, Malika Salimova, Hua Pei, Tracey Lin, Andrew Mead, Zeyang Li, Mark Humayun, Nicos A. Petasis, Alan L. Epstein, and Stan G. Louie

# TABLE OF CONTENTS

- 2398** **A Benzenesulfonamide-Based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer**  
Fangfang Bi, Ziyang Jiang, Wonmin Park, Tobias M.P. Hartwich, Zhiping Ge, Kay Y. Chong, Kevin Yang, Madeline J. Morrison, Dongin Kim, Jaeyeon Kim, Wen Zhang, Lilia M. Kril, David S. Watt, Chunming Liu, and Yang Yang-Hartwich
- 2410** **Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer**  
Byoung Se Lee, Min Hwan Kim, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Kyongkyu Lee, Hyeon Seok Kim, Mi Hyun Kim, Hee Seup Kil, Sang Jin Han, Yong Jin Lee, Kyo Chul Lee, Sang Moo Lim, and Dae Yoon Chi
- 2420** **Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer**  
Ailed Cruz-Collazo, Jean F. Ruiz-Calderon, Hector Picon, Luis D. Borrero-Garcia, Irmaris Lopez, Linette Castillo-Pichardo, Maria del Mar Maldonado, Jorge Duconge, Julia I. Medina, Marvin J. Bayro, Eliud Hernández-O'Farrill, Cornelis P. Vlaar, and Suranganie Dharmawardhane
- 2433** **Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance**  
Célia Cintas, Thibault Douche, Zahra Dantes, Emmanuelle Mouton-Barbosa, Marie-Pierre Bousquet, Coralie Cayron, Nicole Therville, Frédéric Pont, Fernanda Ramos-Delgado, Camille Guyon, Barbara Garmy-Susini, Paola Cappello, Odile Burllet-Schiltz, Emilio Hirsch, Anne Gomez-Brouchet, Benoît Thibault, Maximilian Reichert, and Julie Guillermet-Guibert
- 2446** **Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations**  
Brion W. Murray, Evan Rogers, Dayong Zhai, Wei Deng, Xi Chen, Paul A. Sprengeler, Xin Zhang, Armin Graber, Siegfried H. Reich, Shanna Stopatschinskaja, Benjamin Solomon, Benjamin Besse, and Alexander Drilon
- 2469** **Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment**  
Masakazu Hashimoto, John David Konda, Stephanie Perrino, Maria Celia Fernandez, Andrew M. Lowy, and Pnina Brodt
- 2483** **Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199**  
Beatrice T. Wang, Tasnim Kothambawala, Ling Wang, Thomas J. Matthew, Susan E. Calhoun, Avneesh K. Saini, Maya F. Kotturi, Genevive Hernandez, Eric W. Humke, Marvin S. Peterson, Angus M. Sinclair, and Bruce A. Keyt
- 2495** **Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer**  
Shigehiro Tsujii, Satoshi Serada, Minoru Fujimoto, Sunao Uemura, Tsutomu Namikawa, Taisei Nomura, Ichiro Murakami, Kazuhiro Hanazaki, and Tetsuji Naka
- 2506** **Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression**  
Tianyuan Wang, Adnin Ashrafi, Purna Chaitanya Konduri, Poorva Ghosh, Sanchareeka Dey, Parsa Modareszadeh, Narges Salamat, Parinaz Sadat Alemi, Eranda Berisha, and Li Zhang
- 2519** **Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy**  
Toshiki Iwai, Masamichi Sugimoto, Hina Patel, Keigo Yorozu, Mitsue Kurasawa, and Osamu Kondoh

## TARGETING DRUG RESISTANCE

## LARGE MOLECULE THERAPEUTICS

- 2457** **IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer**  
Spas Dimitrov Markov, Thomas C. Caffrey, Kelly A. O'Connell, James A. Grunkemeyer, Simon Shin, Ryan Hanson, Prathamesh P. Patil, Surendra K. Shukla, Daisy Gonzalez, Ayrienne J. Crawford, Krysten E. Vance, Ying Huang, Kirsten C. Eberle, Prakash Radhakrishnan, Paul M. Grandgenett, Pankaj K. Singh, Ragupathy Madiyalakan, Tracy R. Daniels-Wells, Manuel L. Penichet, Christopher F. Nicodemus, Jill A. Poole, Elizabeth M. Jaffee, Michael A. Hollingsworth, and Kamiya Mehla
- 2527** **Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells**  
Liyuan Yin, Yi Zhang, Lijuan Yin, Yan Ou, Michael S. Lewis, Ruoxiang Wang, Haiyen E. Zhou, Qinghua Zhou, and Leland W.K. Chung

# TABLE OF CONTENTS

**2539 Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-ST5 1001 Randomized Phase III Trial**

Javier Martin-Broto, Maria Lopez-Alvarez, David S. Moura, Rafael Ramos, Paola Collini, Cleofe Romagosa, Silvia Bagué, Salvatore L. Renne, Marta Barisella, Valerie Velasco, Jean-Michel Coindre, Daniel Lopez-Lopez, Joaquin Dopazo, Marco Gambarotti, Luca Braglia, Domenico Franco Merlo, Emanuela Palmerini, Silvia Stacchiotti, Vittorio L. Quagliuolo, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Antonella Brunello, Antonio Gutierrez, Claudia Valverde, Nadia Hindi, Angelo Paolo Dei Tos, Piero Picci, Paolo G. Casali, and Alessandro Gronchi

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

**2553 Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer**

Yang Hu, Baraa K. Manasrah, Stephanie M. McGregor, Robert F. Lera, Roshan X. Norman, John B. Tucker, Christina M. Scribano, Rachel E. Yan, Mouhita Humayun, Kari B. Wisinski, Amye J. Tevaarwerk, Ruth M. O'Regan, Lee G. Wilke, Beth A. Weaver, David J. Beebe, Ning Jin, and Mark E. Burkard

## ABOUT THE COVER

Dysregulation of PMRT5 occurs in various cancers, including lymphomas, lung cancers, and breast cancers. Due to the long residence binding time of JNJ-64619178, a novel PRMT5 inhibitor, the compound exhibits long-lasting target engagement that resists washout. JNJ-63619178 demonstrated potent anti-proliferative activity, supporting its continued clinical study. Read the full article on page 2317.

doi: 10.1158/1535-7163.MCT-20-12-CVR

**2568 Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors**

Gustav Johansson, Marta Berndsen, Stefan Lindskog, Tobias Österlund, Henrik Fagman, Andreas Muth, and Anders Ståhlberg


**2577 Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer**

Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. VanderWalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes Jr, Alexander I. Spira, W. Michael Korn, Edward S. Kim, Stephen V. Liu, and Hossein Borghaei

## MODELS AND TECHNOLOGIES

**2585 Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences**

Cesar A. Garcia, Adip G. Bhargav, Mieu Brooks, Paola Suárez-Meade, Sujana K. Mondal, Natanael Zarco, Karim ReFaey, Mark Jentoft, Erik H. Middlebrooks, Matija Snuderl, Anna Carrano, Hugo Guerrero-Cazares, Paula Schiapparelli, Rachel Sarabia-Estrada, and Alfredo Quiñones-Hinojosa



# Molecular Cancer Therapeutics

**20 (12)**

*Mol Cancer Ther* 2021;20:2315-2597.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/20/12>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/12>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.